Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Apellis Pharmaceuticals, Inc. (APLS) had Non-Operating Income/Expense of $-6.87M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$458.58M |
|
$215.72M |
|
$24.53M |
|
$434.05M |
|
$235.40M |
|
$223.18M |
|
|
Non-Operating Income/Expense |
$-6.87M |
$216.32M |
|
$216.32M |
|
$215.72M |
|
$215.72M |
|
$215.72M |
|
$215.72M |
|
$223.18M |
|
$224.16M |
|
126.42M |
|
130.07M |
|
$1.71 |
|
$1.67 |
|
| Balance Sheet Financials | |
$990.68M |
|
$1.93M |
|
$68.05M |
|
$1.06B |
|
$279.53M |
|
$361.09M |
|
$378.03M |
|
$657.55M |
|
$401.17M |
|
$401.17M |
|
$401.17M |
|
126.50M |
|
| Cash Flow Statement Financials | |
$59.50M |
|
$-0.20M |
|
$7.62M |
|
$412.61M |
|
$480.60M |
|
$67.99M |
|
$82.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.54 |
|
-- |
|
-- |
|
0.47 |
|
1.13 |
|
94.65% |
|
48.67% |
|
48.67% |
|
-- |
|
47.17% |
|
47.04% |
|
$59.30M |
|
-- |
|
-- |
|
-- |
|
0.43 |
|
0.20 |
|
1.33 |
|
67.81 |
|
53.77% |
|
53.77% |
|
20.38% |
|
28.30% |
|
$3.17 |
|
$0.46 |
|
$0.46 |
|